Climate change and human activities severely impact the viability of plants and ecosystems, threatening the environment, biodiversity, and the sustainable development of plant-based products. Biotic and abiotic (ecosystem) determinants affect species distribution and long-term survival, which in turn influence the quality of plants used as herbal medicines and other high-value products. In recent decades, diverse anthropogenic impacts have significantly affected these quality aspects. Climate change, excessive plant exploitation, habitat loss, species vulnerability, and other factors have adversely affected the growth, reproduction, and adaptation of species populations, as well as the quality and volume of primary plant materials supplied to pharmaceutical markets. Despite these growing challenges, there is limited knowledge of potential strategies to prevent or mitigate these impacts, particularly for vulnerable species collected from the wild or harvested from traditional production systems. Hence, effective strategies for preserving and increasing plant populations are urgently needed. In this study, we propose a new framework including the main sustainability factors to better understand and address the vulnerability of a species, hence mitigate the impact of climate change. We assess the applicability of our proposed framework via seven case studies of vulnerable species (i.e., Aquilaria malaccensis Lam., Boswellia sacra Flück., Crocus sativus L., Panax quinquefolius L., Pilocarpus microphyllus Stapf ex Wardlew., Rhodiola rosea L., and Warburgia salutaris (G.Bertol.) Chiov.) from main biogeographic realms, all widely used as medicinal plants. These species present various challenges related to the sustainability of their use, impacting their current and future status locally and globally. Their economic importance, combined with rising demands and specific risks of overexploitation, are also key factors considered here. The suggested framework for the sustainability of medicinal and other high-value plant-based products in the phytopharmaceutical industry emphasises strategies that promote conservation and sustainable resource use. It can also be adapted for other vulnerable species requiring urgent attention.

Background: Carotenoids are bioactive tetraterpenoid C40 pigments that are actively synthesized by plants, bacteria, and fungi. Compounds such as α-carotene, β-carotene, lycopene, lutein, astaxanthin, β-cryptoxanthin, fucoxanthin, and zeaxanthin have attracted increasing attention for their antiaging properties. They exhibit antioxidant, neuroprotective, and anti-inflammatory properties, contributing to the prevention and treatment of age-related diseases. Objectives: The aim of this study was to comprehensively analyze the pharmacological potential and biological mechanisms of carotenoids associated with age-related disorders and to evaluate their application in nutraceuticals, pharmaceuticals, and cosmeceuticals. Methods: A systematic review of studies published over the past two decades was conducted using the databases PubMed, Scopus, and Web of Science. The selection criteria included clinical, in silico, in vivo, and in vitro studies investigating the pharmacological and therapeutic effects of carotenoids. Results: Carotenoids demonstrate a variety of health benefits, including the prevention of age-related macular degeneration, cancer, cognitive decline, metabolic disorders, and skin aging. Their role in nutraceuticals is well supported by their ability to modulate oxidative stress and inflammatory pathways. In pharmaceuticals, carotenoids show promising results in formulations targeting neurodegenerative diseases and metabolic disorders. In cosmeceuticals, they improve skin health by protecting it against UV radiation and oxidative damage. However, bioavailability, optimal dosages, toxicity, and interactions with other bioactive compounds remain critical factors to maximize therapeutic efficacy and still require careful evaluation by scientists. Conclusions: Carotenoids are promising bioactive compounds for antiaging interventions with potential applications in a variety of fields. Further research is needed to optimize their formulas, improve bioavailability, and confirm their long-term safety and effectiveness, especially in the aging population.

The major groups of antioxidant compounds (isoflavonoids, xanthones, hydroxycinnamic acids) in the rhizome methanol extracts of four Ukrainian Iris sp. (Iris pallida, Iris hungarica, Iris sibirica, and Iris variegata) were qualitatively and quantitatively analyzed using HPLC-DAD and UPLC-MS/MS. Gallic acid, caffeic acid, mangiferin, tectoridin, irigenin, iristectorigenin B, irisolidone, 5,6-dihydroxy-7,8,3′,5′-tetramethoxyisoflavone, irisolidone-7-O-β-d-glucopyranoside, germanaism B, and nigricin were recognized by comparing their UV/MS spectra, chromatographic retention time (tR) with those of standard reference compounds. I. hungarica and I. variegata showed the highest total amount of phenolic compounds. Germanaism B was the most abundant component in the rhizomes of I. variegata (7.089 ± 0.032 mg/g) and I. hungarica (6.285 ± 0.030 mg/g). The compound analyses showed good calibration curve linearity (r² > 0.999) and low detection and quantifications limit. These results validated the method for its use in the simultaneous quantitative evaluation of phenolic compounds in the studied Iris sp. I. hungarica and I. variegata rhizomes exhibited antioxidant activity, as demonstrated by the HPLC-ABTS system and NRF2 expression assay and anti-inflammatory activity on respiratory burst in human neutrophils. Moreover, the extracts showed anti-allergic and cytotoxic effects against cancer cells. Anti-coronavirus 229E and lipid formation activities were also evaluated. In summary, potent antioxidant marker compounds were identified in the examined Iris sp.